FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang(Georgetown University), Moshe Levi, Enrico Gratton(University of California, Irvine), Komuraiah Myakala(University of Colorado Anschutz Medical Campus), Suman Ranjit(Fluor (United States)), Kammi Henriksen(University of Chicago), Avi Z. Rosenberg, David J. Orlicky(University of Colorado Anschutz Medical Campus), Jeffrey B. Kopp(Kidney Care UK), Jonathan Levi(National Institutes of Health), Gabriel García(University of Colorado Denver), Yuhuan Luo(University of Colorado Anschutz Medical Campus), Evgenia Dobrinskikh(Inserm), Luciano Adorini(Intercept Pharmaceuticals (United States)), Michal Herman‐Edelstein(Rabin Medical Center), Mark Pruzanski(University of Padua), Kristopher W. Krausz(National Institutes of Health), Amanda Field(Children's National), Frank J. Gonzalez(National Institutes of Health), Yingqiong Peng(University of Colorado Anschutz Medical Campus), Dong Wang(University of Colorado Denver), Ashley Hill(Children's National), Scott Lucia(University of Colorado Anschutz Medical Campus), Liru Qiu(University of Colorado Anschutz Medical Campus), Tao Jiang(Chongqing Medical University), Vivette D. D’Agati(Columbia University), Alexander Dvornikov(Fluor (United States)), Cen Xie(Shanghai Institute of Materia Medica)
Cited by 222
Related Papers
Triglycerides and Cardiovascular Disease
|Circulation|2011|1.9k
The Phasor Approach to Fluorescence Lifetime Imaging Analysis
|Biophysical Journal|2007|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy
|Journal of the American Society of Nephrology|2011|856
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
|Nature Genetics|2008|706